Physician profile
Melissa Phillips
NPI 1447635628
$3,674.38
in general payments reported to CMS, 2019-2025
25 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $290 · 2023: $815 · 2024: $911 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,982.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $600.92 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $530.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $316.85 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor |
| Sequel Med Tech, LLC | $285.96 | 2025 | Twiist |
| Insulet Corporation | $259.63 | 2022-2025 | Omnipod, Omnipod |
| Xeris Pharmaceuticals, INC. | $205.34 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $189.57 | 2021-2023 | Mounjaro, Jardiance |
| Horizon Therapeutics Plc | $189.23 | 2023 | Tepezza |
| Abbott Laboratories | $177.30 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $158.75 | 2024-2025 | |
| Corcept Therapeutics | $144.68 | 2024 | Korlym |
| Cequr Corporation | $124.56 | 2023-2024 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $108.29 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $55.42 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.30 | 2021-2024 | Synjardy, Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $48.56 | 2025 | |
| Sanofi-Aventis U.S. LLC | $44.01 | 2021-2022 | |
| Beta Bionics, INC. | $25.01 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $22.68 | 2023 | |
| Nevro Corp. | $21.37 | 2023 | Senza |
| Kyowa Kirin, INC. | $18.00 | 2025 | |
| Amgen INC. | $16.53 | 2024 | Prolia, Evenity |
| Alexion Pharmaceuticals, INC. | $15.85 | 2022 | |
| Pfizer INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.